The earnings call highlighted significant revenue growth and strong pipeline progress, alongside effective expense management and a robust cash position. However, these positives were offset by challenges in maintaining software gross margins, difficulties in the biotech segment, and continued net losses. The sentiment is balanced with notable progress and ongoing challenges.

Company Guidance

During Schrodinger's second-quarter 2025 financial call, the company provided key guidance metrics and updates on its strategic initiatives. Total revenue for the quarter was reported at $54.8 million, marking a 16% increase compared to the same period in 2024. Software revenue accounted for $40.5 million, growing by 15% year-over-year, while drug discovery revenue reached $14.2 million. The company reaffirmed its full-year guidance, projecting software revenue growth between 10% to 15% and drug discovery revenue between $45 million to $50 million. Schrodinger highlighted its ongoing progress in the development of its proprietary drugs, including SGR-1505, SGR-2921, and SGR-3515, with expectations to present initial Phase I data for the latter two in the fourth quarter. The company continues to make enhancements to its software platform and is advancing its predictive toxicology initiative, aligning with the FDA's push for new alternative methods to reduce animal testing. Operating expenses were reported at $79 million, a decrease of 6% from the previous year, attributed to a $30 million expense reduction initiative. Schrodinger remains well-capitalized with $462 million in cash and equivalents, and is exploring strategic opportunities for partnership and out-licensing to accelerate the development of its drug programs.

Revenue Growth

Total revenue was $54.8 million in the second quarter, a 16% increase from the second quarter of 2024. Software revenue was $40.5 million, representing 15% year-over-year growth, while drug discovery revenue was $14.2 million, a 19% increase compared to Q2 2024.

Strong Pipeline Progress

15 development candidates from the collaborative and proprietary portfolio have entered Phase I clinical development, with six advancing to Phase II and one in Phase III. Notable progress was made with SGR-1505, showing best-in-class potential and receiving FDA Fast Track designation.

Expense Management

R&D expenses decreased by over 15%, and total operating expenses were $79 million, a decrease of 6% compared to Q2 2024, largely due to a $30 million expense reduction initiative.

Cash Position

The company remains well-capitalized with $462 million in cash and equivalents as of June 30, 2025.

Schrodinger (SDGR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SDGR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.73 / -	-0.52	―	―	―
Aug 06, 2025	2025 (Q2)	-0.77 / -0.59	-0.74	20.27% (+0.15)
May 07, 2025	2025 (Q1)	-0.73 / -0.82	-0.76	-7.89% (-0.06)
Feb 26, 2025	2024 (Q4)	-0.42 / -0.55	-0.32	-71.88% (-0.23)
Nov 12, 2024	2024 (Q3)	-0.63 / -0.52	-0.86	39.53% (+0.34)
Jul 31, 2024	2024 (Q2)	-0.83 / -0.74	0.06	-1333.33% (-0.80)
May 01, 2024	2024 (Q1)	-0.74 / -0.76	1.75	-143.43% (-2.51)
Feb 28, 2024	2023 (Q4)	-0.40 / -0.32	-0.39	17.95% (+0.07)
Nov 01, 2023	2023 (Q3)	-0.69 / -0.86	-0.56	-53.57% (-0.30)
Aug 02, 2023	2023 (Q2)	-0.51 / 0.06	-0.67	108.96% (+0.73)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SDGR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$19.34	$19.36	+0.10%
May 07, 2025	$23.72	$23.88	+0.67%
Feb 26, 2025	$21.70	$22.25	+2.53%
Nov 12, 2024	$19.54	$22.25	+13.87%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.